Cardiometabolic Health Benefits of a Sustainable Grape Seed Extract supplementation on Elevated Blood Pressure and Stage 1 Hypertension: Results from a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial

Q: What are the key findings of this study?

Grape seed extract supplementation significantly reduced systolic blood pressure by 8.15 mmHg and diastolic blood pressure by 4.85 mmHg compared to placebo after 8 weeks.

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Elevated blood pressure or Stage 1 hypertension (n=80). Intervention: Sustainable grape seed extract (GSEe) vs. Placebo. Primary outcome: Change in systolic blood pressure at 8 weeks (MD -8.15, 95% CI -11.43 to -4.87, p=<0.001).

Q: What does this research mean for the field?

Grape seed extract supplementation significantly reduces systolic blood pressure by 8.15 mmHg and diastolic blood pressure by 4.85 mmHg compared to placebo after 8 weeks in individuals with elevated blood pressure or stage 1 hypertension. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To assess the effects of grape seed extract supplementation versus placebo for 8 weeks on blood pressure, lipid profile, systemic inflammation, and psychological well-being in adults with early-stage blood pressure dysregulation.

Amjad Khan; Salma Zeb; Somia Iqtadar; Fazle Rabbani; Wardah Mohsin; Muhammad NA Chaudhry; Ayesha Kanwal; Ikramuddin Ujjan; Paola Misiano; Giovanna Petrangolini; Rahat jamil; Gabriele Conti

doi:10.26502/jfsnr.2642-110000196

January 1, 2026Journal of Food Science and Nutrition ResearchOpen Access

Cardiometabolic Health Benefits of a Sustainable Grape Seed Extract supplementation on Elevated Blood Pressure and Stage 1 Hypertension: Results from a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial

View Full Paper

Ask AI

Bookmark

Share

Key result

Grape seed extract lowers systolic blood pressure by ~8 mmHg compared with placebo.

MD -8.15
95% CI -11.43 to -4.87
P<0.001
n=80

Why the study?

Elevated blood pressure and Stage 1 hypertension are early cardiovascular risk stages where non-pharmacological interventions like grape seed extract supplementation have limited controlled clinical evidence.

Does grape seed extract supplementation reduce systolic and diastolic blood pressure in adults with elevated blood pressure or Stage 1 hypertension?

Key Points

To assess the effects of grape seed extract supplementation versus placebo for 8 weeks on blood pressure, lipid profile, systemic inflammation, and psychological well-being in adults with early-stage blood pressure dysregulation.
Multicenter, double-blind, randomized, placebo-controlled trial enrolling 80 adults with elevated blood pressure or Stage 1 hypertension.
Participants were randomized 1:1 to receive either sustainable oral grape seed extract (2 × 150 mg daily, n=40) or placebo (n=40) for 8 weeks.
At 8 weeks, systolic blood pressure was significantly lower in the grape seed extract group versus placebo (mean difference: -8.15 mmHg; 95% CI: -11.43 to -4.87; p < 0.001), with a within-group decrease of -7.80 mmHg (95% CI: -10.55 to -5.05; p < 0.0001).
Diastolic blood pressure was significantly lower in the grape seed extract group compared with placebo at 8 weeks (-4.85 mmHg; 95% CI: -8.41 to -1.29; p = 0.008), reflecting a within-group reduction of -10.05 mmHg (95% CI: -13.17 to -6.93; p < 0.0001).
Direct low-density lipoprotein cholesterol decreased in the grape seed extract group from 138.2 ± 7.3 mg/dL at baseline to 111.4 ± 4.9 mg/dL at 8 weeks (-26.8 mg/dL; p = 0.0008), alongside reductions in systemic inflammation (hs-CRP) and perceived stress.

Study Design

Type

RCT (n=80)

Blinding

Double-blind

Randomization

1:1 ratio, 6-block randomization

Multicenter

Yes

Structured PICO

Does grape seed extract supplementation reduce systolic and diastolic blood pressure in adults with elevated blood pressure or Stage 1 hypertension?

P

Population

80 adults aged 30-80 years with elevated blood pressure or Stage 1 hypertension, free from recent antihypertensive medication, followed for 8 weeks.

I

Intervention

Grape seed extract (GSEe) 150 mg oral tablet twice daily for 8 weeks (participants instructed to maintain usual diet and physical activity).

C

Comparator

Matching placebo tablets (identical inert excipients, appearance, size, color, and packaging) twice daily for 8 weeks (participants instructed to maintain usual diet and physical activity).

O

Outcome

Changes in systolic and diastolic blood pressure at 8 weeks.surrogate

Main Result

Mean Difference: -8.15 (95% CI -11.43–-4.87)

p-value: p=<0.001

Implication

Supplementation with sustainable grape seed extract for 8 weeks significantly reduces systolic and diastolic blood pressure and improves lipid profiles in adults with elevated blood pressure or Stage 1 hypertension.

Abstract

Background: Elevated blood pressure (BP) and Stage 1 hypertension represent early stages of cardiovascular risk where non-pharmacological interventions are recommended.Grape, a polyphenolic antioxidant, has shown potential BP-lowering and cardiometabolic benefits, but controlled clinical evidence remains limited.Objective: Aim of the study was modulation of BP, lipid profile, systemic inflammation, psychological well-being, lipid, after grape supplementation vs placebo for 8 weeks in individuals at an early stage of BP dysregulation. Methods:In this multicenter, randomized, double-blind, placebocontrolled clinical trial, 80 adults with elevated BP or Stage 1 hypertension were randomized to receive either a sustainable oral grape seed extract (GSEe) supplement, 2x150 mg daily, or placebo for 8 weeks.Primary outcomes were changes in systolic and diastolic BP.Secondary outcomes included lipid profile, high-sensitivity C-reactive protein (hs-CRP), and psychological well-being assessed by the Positive and Negative Affect Schedule (PANAS), perceived stress (PSQ-30), and health-related quality of life (QoL) questionnaires.Results: GSEe supplementation resulted in significant between-group differences versus placebo (p < 0.01), and progressive reductions in systolic (-7.8 mmHg) and diastolic BP (-10.1 mmHg) at 8 weeks compared with baseline.Favorable effects on cardiometabolic parameters were observed, including reductions in LDL cholesterol and attenuation of non-HDL cholesterol progression.Systemic inflammation (hs-CRP) decreased in the GSEe group.Psychological outcomes showed improvements in affective status, alongside in QoL domains and reductions in PSQ-30.Conclusion: Supplementation with a sustainable GSEe improved blood pressure, lipid profile, inflammatory status, and psychological well-being, in adults at an early stage of BP dysregulation, supporting GSEe benefits in early cardiovascular risk management.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khan et al. (2026) conducted an RCT in Elevated blood pressure or Stage 1 hypertension (n=80). Sustainable grape seed extract (GSEe) vs. Placebo was evaluated on Change in systolic blood pressure at 8 weeks (MD -8.15, 95% CI -11.43 to -4.87, p=<0.001). Grape seed extract supplementation significantly reduced systolic blood pressure by 8.15 mmHg and diastolic blood pressure by 4.85 mmHg compared to placebo after 8 weeks.

synapsesocial.com/papers/6ad0fc963afa093ea9acfecb https://doi.org/10.26502/jfsnr.2642-110000196

View Full Paper

Ask AI

Bookmark

Share

Cardiometabolic Health Benefits of a Sustainable Grape Seed Extract supplementation on Elevated Blood Pressure and Stage 1 Hypertension: Results from a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial

Key Points

Study Design

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Cardiometabolic Health Benefits of a Sustainable Grape Seed Extract supplementation on Elevated Blood Pressure and Stage 1 Hypertension: Results from a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial

Key Points

Study Design

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading